Delivery Order SPE2DB24D1021-SPE2DB25FFAEL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors on August 18, 2025, with a ceiling value of $3,291.68 and ultimate completion date of August 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injections valued at $11,887.80. This is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and was competitively awarded without set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a pharmaceutical distributor and critical federal...
- The Defense Logistics Agency (DLA) awarded a $1,172.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract represents a single delivery order fulfilling federal pharmaceutical procurement needs for military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,996.67 for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on August 26, 2025, with an ultimate completion date of August 27, 2025. This is a firm fixed-price, non-set-aside contract to be performed at the company's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal pharmaceutical supply relationship,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors in 0.5 mL quantities, with a ceiling value of $1,906.45. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and is scheduled for completion by August 28, 2025. The delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors, with a contract ceiling value of $24,832.86 and an ultimate completion date of August 18, 2025. This is a firm fixed-price, competitive delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors with a ceiling value of $1,143.87. This is a firm fixed-price delivery order with an ultimate completion date of September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under an existing contract vehicle, reflecting...
- The Defense Logistics Agency awarded a $34,076.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injectors. This non-competitive, non-set-aside delivery order is scheduled for ultimate completion on July 29, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role as a pharmaceutical...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFAELDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors with a ceiling value of $4,379.74 and ultimate completion date of September 4, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open competition. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the company's primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor, AmerisourceBergen supplies critical medical commodities including specialty medications, brand-name and generic drugs, and medical devices to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The pharmaceutical product being delivered supports DLA's medical supply chain requirements for military personnel and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 9/3/25 |